// App-Quantinova.ai

378 : Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti-Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy Among Rheumatoid Arthritis Patients in a Real-World Setting

Researchers

Presenter

  • Nicole M. Engel-Nitz

Principal Investigators

  • Sarika Ogale

  • Mahesh Kulakodlu

Medical Centers

  • Observational Research, OptumInsight, Eden Prairie, MN

Locations

  • United States

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Certolizumab pegol

  • Hydroxychloroquine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • D-penicillamine

  • Penicillamine

  • Sulfasalazine

  • Oraprine

  • Cyclosporine eent

  • Methotrexate

  • HWA-486

  • Adalimumab

  • Infliximab

  • Etanercept

  • CHS-0214

  • golimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved